These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 2260966)

  • 81. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
    Taplin ME; Bubley GJ; Shuster TD; Frantz ME; Spooner AE; Ogata GK; Keer HN; Balk SP
    N Engl J Med; 1995 May; 332(21):1393-8. PubMed ID: 7723794
    [TBL] [Abstract][Full Text] [Related]  

  • 82. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
    Korpal M; Korn JM; Gao X; Rakiec DP; Ruddy DA; Doshi S; Yuan J; Kovats SG; Kim S; Cooke VG; Monahan JE; Stegmeier F; Roberts TM; Sellers WR; Zhou W; Zhu P
    Cancer Discov; 2013 Sep; 3(9):1030-43. PubMed ID: 23842682
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The LNCaP cell line--a new model for studies on human prostatic carcinoma.
    Horoszewicz JS; Leong SS; Chu TM; Wajsman ZL; Friedman M; Papsidero L; Kim U; Chai LS; Kakati S; Arya SK; Sandberg AA
    Prog Clin Biol Res; 1980; 37():115-32. PubMed ID: 7384082
    [No Abstract]   [Full Text] [Related]  

  • 85. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
    Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
    Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
    Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.
    Gaddipati JP; McLeod DG; Heidenberg HB; Sesterhenn IA; Finger MJ; Moul JW; Srivastava S
    Cancer Res; 1994 Jun; 54(11):2861-4. PubMed ID: 8187068
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Androgen receptor gene mutations in human prostate cancer.
    Suzuki H; Sato N; Watabe Y; Masai M; Seino S; Shimazaki J
    J Steroid Biochem Mol Biol; 1993 Dec; 46(6):759-65. PubMed ID: 8274409
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups.
    Zaman N; Giannopoulos PN; Chowdhury S; Bonneil E; Thibault P; Wang E; Trifiro M; Paliouras M
    PLoS One; 2014; 9(11):e113190. PubMed ID: 25409505
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
    Rathkopf DE; Smith MR; Ryan CJ; Berry WR; Shore ND; Liu G; Higano CS; Alumkal JJ; Hauke R; Tutrone RF; Saleh M; Chow Maneval E; Thomas S; Ricci DS; Yu MK; de Boer CJ; Trinh A; Kheoh T; Bandekar R; Scher HI; Antonarakis ES
    Ann Oncol; 2017 Sep; 28(9):2264-2271. PubMed ID: 28633425
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
    Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME
    Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Plasma AR and abiraterone-resistant prostate cancer.
    Romanel A; Gasi Tandefelt D; Conteduca V; Jayaram A; Casiraghi N; Wetterskog D; Salvi S; Amadori D; Zafeiriou Z; Rescigno P; Bianchini D; Gurioli G; Casadio V; Carreira S; Goodall J; Wingate A; Ferraldeschi R; Tunariu N; Flohr P; De Giorgi U; de Bono JS; Demichelis F; Attard G
    Sci Transl Med; 2015 Nov; 7(312):312re10. PubMed ID: 26537258
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The mutational landscape of lethal castration-resistant prostate cancer.
    Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
    Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
    Watson PA; Arora VK; Sawyers CL
    Nat Rev Cancer; 2015 Dec; 15(12):701-11. PubMed ID: 26563462
    [TBL] [Abstract][Full Text] [Related]  

  • 97. In vivo amplification of the androgen receptor gene and progression of human prostate cancer.
    Visakorpi T; Hyytinen E; Koivisto P; Tanner M; Keinänen R; Palmberg C; Palotie A; Tammela T; Isola J; Kallioniemi OP
    Nat Genet; 1995 Apr; 9(4):401-6. PubMed ID: 7795646
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol.
    Elo JP; Kvist L; Leinonen K; Isomaa V; Henttu P; Lukkarinen O; Vihko P
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3494-500. PubMed ID: 8530589
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Androgen receptor defects: historical, clinical, and molecular perspectives.
    Quigley CA; De Bellis A; Marschke KB; el-Awady MK; Wilson EM; French FS
    Endocr Rev; 1995 Jun; 16(3):271-321. PubMed ID: 7671849
    [No Abstract]   [Full Text] [Related]  

  • 100. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
    Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
    Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.